2022. Real-world data on the incidence of immune-related adverse events associated with anti-PD-1/PD-L1 treatment in Russia. Voprosy onkologii. 68, 2 (May 2022), 188–199. DOI:https://doi.org/10.37469/0507-3758-2022-68-2-188-199.